Surgery as a double-edged sword: A clinically feasible approach to overcome the metastasis-promoting effects of surgery by blunting stress and prostaglandin responses

Cancers

Volumn 2, Issue 4, 2010, Pages 1929-1951

  Benish, Marganit ^a   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; Immunosuppression; Natural killer cells; Perioperative period; Prophylactic interventions; Stress; Surgery

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CASPASE 3; CASPASE 9; CATECHOLAMINE; CELECOXIB; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETODOLAC; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HALOTHANE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KETAMINE; MORPHINE; NADOLOL; NORADRENALIN; OPIATE RECEPTOR; PROPRANOLOL; PROSTAGLANDIN; PROSTAGLANDIN E2; THIOPENTAL;

ANALGESIA; APOPTOSIS; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST SURGERY; CANCER CELL; CANCER RECURRENCE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; ESTRUS CYCLE; GENERAL ANESTHESIA; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LAPAROSCOPIC SURGERY; METASTASIS POTENTIAL; NATURAL KILLER CELL; NONHUMAN; PAIN; PHYSIOLOGICAL STRESS; POSTOPERATIVE PAIN; REVIEW; RISK FACTOR; STRESS; TUMOR GROWTH;

EID: 79952265384     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2041929     Document Type: Review

References (167)

1. Bonnema, J.; van de Velde, C.J. Sentinel lymph node biopsy in breast cancer. Ann. Oncol. 2002, 13, 1531-1537.
2. Fisher, B.; Bauer, M.; Wickerham, D.L.; Redmond, C.K.; Fisher, E.R.; Cruz, A.B.; Foster, R.; Gardner, B.; Lerner, H.; Margolese, R.; et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An nsabp update. Cancer 1983, 52, 1551-1557.
3. Veronesi, U.; Paganelli, G.; Viale, G.; Luini, A.; Zurrida, S.; Galimberti, V.; Intra, M.; Veronesi, P.; Robertson, C.; Maisonneuve, P.; Renne, G.; De Cicco, C.; De Lucia, F.; Gennari, R. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 2003, 349, 546-553.
4. Salem, A.A.; Douglas-Jones, A.G.; Sweetland, H.M.; Mansel, R.E. Intraoperative evaluation of axillary sentinel lymph nodes using touch imprint cytology and immunohistochemistry. Part ii. Results. Eur. J. Surg. Oncol. 2006, 32, 484-487.
5. Yamaguchi, K.; Takagi, Y.; Aoki, S.; Futamura, M.; Saji, S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 2000, 232, 58-65.
6. Shariat, S.F.; Kattan, M.W.; Song, W.; Bernard, D.; Gottenger, E.; Wheeler, T.M.; Slawin, K.M. Early postoperative peripheral blood reverse transcription pcr assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 2003, 63, 5874-5878.
7. Biki, B.; Mascha, E.; Moriarty, D.C.; Fitzpatrick, J.M.; Sessler, D.I.; Buggy, D.J. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: A retrospective analysis. Anesthesiology 2008, 109, 180-187.
8. Demicheli, R.; Miceli, R.; Moliterni, A.; Zambetti, M.; Hrushesky, W.J.; Retsky, M.W.; Valagussa, P.; Bonadonna, G. Breast cancer recurrence dynamics following adjuvant cmf is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann. Oncol. 2005, 16, 1449-1457.
9. Pascual, M.; Alonso, S.; Pares, D.; Courtier, R.; Gil, M.J.; Grande, L.; Pera, M. Randomized clinical trial comparing inflammatory and angiogenic response after open versus laparoscopic curative resection for colonic cancer. Br. J. Surg. 2010, doi: 10.1002/bjs.7258.
10. Abramovitch, R.; Marikovsky, M.; Meir, G.; Neeman, M. Stimulation of tumour growth by wound-derived growth factors. Br. J. Cancer 1999, 79, 1392-1398.
11. Ben-Eliyahu, S.; Page, G.G.; Yirmiya, R.; Shakhar, G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int. J. Cancer 1999, 80, 880-888.
12. Melamed, R.; Rosenne, E.; Shakhar, K.; Schwartz, Y.; Abudarham, N.; Ben-Eliyahu, S. Marginating pulmonary-nk activity and resistance to experimental tumor metastasis: Suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 2005, 19, 114-126.
13. McCoy, J.L.; Rucker, R.; Petros, J.A. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res. Treat. 2000, 60, 227-234.
14. Atzil, S.; Arad, M.; Glasner, A.; Abiri, N.; Avraham, R.; Greenfeld, K.; Rosenne, E.; Beilin, B.; Ben-Eliyahu, S. Blood transfusion promotes cancer progression: A critical role for aged erythrocytes. Anesthesiology 2008, 109, 989-997.
15. Ben-Eliyahu, S.; Shakhar, G.; Rosenne, E.; Levinson, Y.; Beilin, B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: A role for adrenergic mechanisms. Anesthesiology 1999, 91, 732-740.
16. Snyder, G.L.; Greenberg, S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br. J. Anaesth. 2010, 105, 106-115.
17. Gao, J.Q.; Okada, N.; Mayumi, T.; Nakagawa, S. Immune cell recruitment and cell-based system for cancer therapy. Pharm. Res. 2008, 25, 752-768.
18. Goldfarb, Y.; Ben-Eliyahu, S. Surgery as a risk factor for breast cancer recurrence and metastasis: Mediating mechanisms and clinical prophylactic approaches. Breast Dis. 2006, 26, 99-114.
19. Shakhar, G.; Ben-Eliyahu, S. Potential prophylactic measures against postoperative immunosuppression: Could they reduce recurrence rates in oncological patients? Ann. Surg. Oncol. 2003, 10, 972-992.
20. Whiteside, T.L. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16, 3-15.
21. Raskovalova, T.; Lokshin, A.; Huang, X.; Jackson, E.K.; Gorelik, E. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by il-2/nkp46-activated nk cells: Involvement of protein kinase a isozyme i (pka i). Immunol. Res. 2006, 36, 91-99.
22. Greenfeld, K.; Avraham, R.; Benish, M.; Goldfarb, Y.; Rosenne, E.; Shapira, Y.; Rudich, T.; Ben-Eliyahu, S. Immune suppression while awaiting surgery and following it: Dissociations between plasma cytokine levels, their induced production, and nk cell cytotoxicity. Brain Behav. Immun. 2007, 21, 503-513.
23. Benish, M.; Bartal, I.; Goldfarb, Y.; Levi, B.; Avraham, R.; Raz, A.; Ben-Eliyahu, S. Perioperative use of beta-blockers and cox-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann. Surg. Oncol. 2008, 15, 2042-2052.
24. Cruz-Munoz, M.E.; Veillette, A. Do nk cells always need a license to kill? Nat. Immunol. 2010, 11, 279-280.
25. Cooper, M.A.; Colonna, M.; Yokoyama, W.M. Hidden talents of natural killers: Nk cells in innate and adaptive immunity. EMBO Rep. 2009, 10, 1103-1110.
26. Algarra, I.; Garcia-Lora, A.; Cabrera, T.; Ruiz-Cabello, F.; Garrido, F. The selection of tumor variants with altered expression of classical and nonclassical mhc class i molecules: Implications for tumor immune escape. Cancer Immunol. Immunother. 2004, 53, 904-910.
27. Ljunggren, H.G.; Karre, K. In search of the 'missing self': Mhc molecules and nk cell recognition. Immunol. Today 1990, 11, 237-244.
28. Brittenden, J.; Heys, S.D.; Ross, J.; Eremin, O. Natural killer cells and cancer. Cancer 1996, 77, 1226-1243.
29. Taketomi, A.; Shimada, M.; Shirabe, K.; Kajiyama, K.; Gion, T.; Sugimachi, K. Natural killer cell activity in patients with hepatocellular carcinoma: A new prognostic indicator after hepatectomy. Cancer 1998, 83, 58-63.
30. Glasner, A.; Avraham, R.; Rosenne, E.; Benish, M.; Zmora, O.; Shemer, S.; Meiboom, H.; Ben-Eliyahu, S. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol. 2010, 184, 2449-2457.
31. Singh-Ranger, G.; Salhab, M.; Mokbel, K. The role of cyclooxygenase-2 in breast cancer: Review. Breast Cancer Res. Treat. 2008, 109, 189-198.
32. Howe, L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007, 9, 210.
33. Sugimoto, Y.; Narumiya, S. Prostaglandin e receptors. J. Biol. Chem. 2007, 282, 11613-11617.
34. Su, Y.; Huang, X.; Raskovalova, T.; Zacharia, L.; Lokshin, A.; Jackson, E.; Gorelik, E. Cooperation of adenosine and prostaglandin e2 (pge2) in amplification of camp-pka signaling and immunosuppression. Cancer Immunol. Immunother. 2008, 57, 1611-1623.
35. Martinet, L.; Jean, C.; Dietrich, G.; Fournie, J.J.; Poupot, R. Pge2 inhibits natural killer and gamma delta t cell cytotoxicity triggered by nkr and tcr through a camp-mediated pka type i-dependent signaling. Biochem. Pharmacol. 2010, 80, 838-845.
36. Zeddou, M.; Greimers, R.; de Valensart, N.; Nayjib, B.; Tasken, K.; Boniver, J.; Moutschen, M.; Rahmouni, S. Prostaglandin e2 induces the expression of functional inhibitory cd94/nkg2a receptors in human cd8+ t lymphocytes by a camp-dependent protein kinase a type i pathway. Biochem. Pharmacol. 2005, 70, 714-724.
37. Chattopadhyay, S.; Bhattacharyya, S.; Saha, B.; Chakraborty, J.; Mohanty, S.; Sakib Hossain, D.M.; Banerjee, S.; Das, K.; Sa, G.; Das, T. Tumor-shed pge(2) impairs il2rgammac-signaling to inhibit cd4 t cell survival: Regulation by theaflavins. PLoS One 2009, 4, e7382.
38. Ahmadi, M.; Emery, D.C.; Morgan, D.J. Prevention of both direct and cross-priming of antitumor cd8+ t-cell responses following overproduction of prostaglandin e2 by tumor cells in vivo. Cancer Res. 2008, 68, 7520-7529.
39. Sharma, S.; Yang, S.C.; Zhu, L.; Reckamp, K.; Gardner, B.; Baratelli, F.; Huang, M.; Batra, R.K.; Dubinett, S.M. Tumor cyclooxygenase-2/prostaglandin e2-dependent promotion of foxp3 expression and cd4+ cd25+ t regulatory cell activities in lung cancer. Cancer Res. 2005, 65, 5211-5220.
40. Yakar, I.; Melamed, R.; Shakhar, G.; Shakhar, K.; Rosenne, E.; Abudarham, N.; Page, G.G.; Ben-Eliyahu, S. Prostaglandin e(2) suppresses nk activity in vivo and promotes postoperative tumor metastasis in rats. Ann. Surg. Oncol. 2003, 10, 469-479.
41. Ono, M. Molecular links between tumor angiogenesis and inflammation: Inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008, 99, 1501-1506.
42. Sahin, M.; Sahin, E.; Gumuslu, S. Cyclooxygenase-2 in cancer and angiogenesis. Angiology 2009, 60, 242-253.
43. Sarkar, F.H.; Adsule, S.; Li, Y.; Padhye, S. Back to the future: Cox-2 inhibitors for chemoprevention and cancer therapy. Mini Rev. Med. Chem. 2007, 7, 599-608.
44. Kundu, N.; Ma, X.; Holt, D.; Goloubeva, O.; Ostrand-Rosenberg, S.; Fulton, A.M. Antagonism of the prostaglandin e receptor ep4 inhibits metastasis and enhances nk function. Breast Cancer Res. Treat. 2009, 117, 235-242.
45. Singh, B.; Irving, L.R.; Tai, K.; Lucci, A. Overexpression of cox-2 in celecoxib-resistant breast cancer cell lines. J. Surg. Res. 2010, 163, 235-243.
46. Singh, B.; Cook, K.R.; Vincent, L.; Hall, C.S.; Berry, J.A.; Multani, A.S.; Lucci, A. Cyclooxygenase-2 induces genomic instability, bcl2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in mcf7 breast cancer cells. J. Surg. Res. 2008, 147, 240-246.
47. Hu, M.; Peluffo, G.; Chen, H.; Gelman, R.; Schnitt, S.; Polyak, K. Role of cox-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl. Acad. Sci. USA 2009, 106, 3372-3377.
48. Minn, A.J.; Gupta, G.P.; Siegel, P.M.; Bos, P.D.; Shu, W.; Giri, D.D.; Viale, A.; Olshen, A.B.; Gerald, W.L.; Massague, J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436, 518-524.
49. Bos, P.D.; Zhang, X.H.; Nadal, C.; Shu, W.; Gomis, R.R.; Nguyen, D.X.; Minn, A.J.; van de Vijver, M.J.; Gerald, W.L.; Foekens, J.A.; Massague, J. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459, 1005-1009.
50. Singh, B.; Berry, J.A.; Vincent, L.E.; Lucci, A. Involvement of il-8 in cox-2-mediated bone metastases from breast cancer. J. Surg. Res. 2006, 134, 44-51.
51. Yoshinaka, R.; Shibata, M.A.; Morimoto, J.; Tanigawa, N.; Otsuki, Y. Cox-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res. 2006, 26, 4245-4254.
52. Qadri, S.S.; Wang, J.H.; Coffey, J.C.; Alam, M.; O'Donnell, A.; Aherne, T.; Redmond, H.P. Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective cox-2 inhibition. Ann. Thorac. Surg. 2005, 79, 990-995; discussion 990-995.
53. Palesh, O.; Butler, L.D.; Koopman, C.; Giese-Davis, J.; Carlson, R.; Spiegel, D. Stress history and breast cancer recurrence. J. Psychosom. Res. 2007, 63, 233-239.
54. Antoni, M.H.; Lutgendorf, S.K.; Cole, S.W.; Dhabhar, F.S.; Sephton, S.E.; McDonald, P.G.; Stefanek, M.; Sood, A.K. The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms. Nat. Rev. Cancer 2006, 6, 240-248.
55. Jetschmann, J.U.; Benschop, R.J.; Jacobs, R.; Kemper, A.; Oberbeck, R.; Schmidt, R.E.; Schedlowski, M. Expression and in-vivo modulation of alpha- and beta-adrenoceptors on human natural killer (cd16+) cells. J. Neuroimmunol. 1997, 74, 159-164.
56. Shakhar, G.; Ben-Eliyahu, S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J. Immunol. 1998, 160, 3251-3258.
57. Dokur, M.; Boyadjieva, N.; Sarkar, D.K. Catecholaminergic control of nk cell cytolytic activity regulatory factors in the spleen. J. Neuroimmunol. 2004, 151, 148-157.
58. Calcagni, E.; Elenkov, I. Stress system activity, innate and t helper cytokines, and susceptibility to immune-related diseases. Ann. NY Acad. Sci. 2006, 1069, 62-76.
59. Sekut, L.; Champion, B.R.; Page, K.; Menius, J.A., Jr.; Connolly, K.M. Anti-inflammatory activity of salmeterol: Down-regulation of cytokine production. Clin. Exp. Immunol. 1995, 99, 461-466.
60. Ramer-Quinn, D.S.; Baker, R.A.; Sanders, V.M. Activated t helper 1 and t helper 2 cells differentially express the beta-2-adrenergic receptor: A mechanism for selective modulation of t helper 1 cell cytokine production. J. Immunol. 1997, 159, 4857-4867.
61. Holen, E.; Elsayed, S. Effects of beta2 adrenoceptor agonists on t-cell subpopulations. APMIS 1998, 106, 849-857.
62. Lee, J.W.; Shahzad, M.M.; Lin, Y.G.; Armaiz-Pena, G.; Mangala, L.S.; Han, H.D.; Kim, H.S.; Nam, E.J.; Jennings, N.B.; Halder, J.; Nick, A.M.; Stone, R.L.; Lu, C.; Lutgendorf, S.K.; Cole, S.W.; Lokshin, A.E.; Sood, A.K. Surgical stress promotes tumor growth in ovarian carcinoma. Clin. Cancer Res. 2009, 15, 2695-2702.
63. Sloan, E.K.; Priceman, S.J.; Cox, B.F.; Yu, S.; Pimentel, M.A.; Tangkanangnukul, V.; Arevalo, J.M.; Morizono, K.; Karanikolas, B.D.; Wu, L.; Sood, A.K.; Cole, S.W. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010, doi: 10.1158/0008-5472.
64. Shi, M.; Liu, D.; Duan, H.; Qian, L.; Wang, L.; Niu, L.; Zhang, H.; Yong, Z.; Gong, Z.; Song, L.; Yu, M.; Hu, M.; Xia, Q.; Shen, B.; Guo, N. The beta2-adrenergic receptor and her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res. Treat. 2010, doi: 10.1007/s10549-010-0822-2.
65. Bookout, A.L.; Finney, A.E.; Guo, R.; Peppel, K.; Koch, W.J.; Daaka, Y. Targeting gbetagamma signaling to inhibit prostate tumor formation and growth. J. Biol. Chem. 2003, 278, 37569-37573.
66. Sastry, K.S.; Karpova, Y.; Prokopovich, S.; Smith, A.J.; Essau, B.; Gersappe, A.; Carson, J.P.; Weber, M.J.; Register, T.C.; Chen, Y.Q.; Penn, R.B.; Kulik, G. Epinephrine protects cancer cells from apoptosis via activation of camp-dependent protein kinase and bad phosphorylation. J. Biol. Chem. 2007, 282, 14094-14100.
67. Thaker, P.H.; Han, L.Y.; Kamat, A.A.; Arevalo, J.M.; Takahashi, R.; Lu, C.; Jennings, N.B.; Armaiz-Pena, G.; Bankson, J.A.; Ravoori, M.; Merritt, W.M.; Lin, Y.G.; Mangala, L.S.; Kim, T.J.; Coleman, R.L.; Landen, C.N.; Li, Y.; Felix, E.; Sanguino, A.M.; Newman, R.A.; Lloyd, M.; Gershenson, D.M.; Kundra, V.; Lopez-Berestein, G.; Lutgendorf, S.K.; Cole, S.W.; Sood, A.K. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 2006, 12, 939-944.
68. Guo, K.; Ma, Q.; Wang, L.; Hu, H.; Li, J.; Zhang, D.; Zhang, M. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol. Rep. 2009, 22, 825-830.
69. Yang, E.V.; Sood, A.K.; Chen, M.; Li, Y.; Eubank, T.D.; Marsh, C.B.; Jewell, S.; Flavahan, N.A.; Morrison, C.; Yeh, P.E.; Lemeshow, S.; Glaser, R. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (mmp)-2, and mmp-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006, 66, 10357-10364.
70. Sood, A.K.; Armaiz-Pena, G.N.; Halder, J.; Nick, A.M.; Stone, R.L.; Hu, W.; Carroll, A.R.; Spannuth, W.A.; Deavers, M.T.; Allen, J.K.; Han, L.Y.; Kamat, A.A.; Shahzad, M.M.; McIntyre, B.W.; Diaz-Montero, C.M.; Jennings, N.B.; Lin, Y.G.; Merritt, W.M.; DeGeest, K.; Vivas-Mejia, P.E.; Lopez-Berestein, G.; Schaller, M.D.; Cole, S.W.; Lutgendorf, S.K. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J. Clin. Invest. 2010, 120, 1515-1523.
71. Baselga, J.; Swain, S.M. Novel anticancer targets: Revisiting erbb2 and discovering erbb3. Nat. Rev. Cancer 2009, 9, 463-475.
72. Carie, A.E.; Sebti, S.M. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the raf-1/mek-1/erk1/2 pathway. Oncogene 2007, 26, 3777-3788.
73. Sarkar, C.; Das, S.; Chakroborty, D.; Chowdhury, U.R.; Basu, B.; Dasgupta, P.S.; Basu, S. Cutting edge: Stimulation of dopamine d4 receptors induce t cell quiescence by up-regulating kruppel-like factor-2 expression through inhibition of erk1/erk2 phosphorylation. J. Immunol. 2006, 177, 7525-7529.
74. Chakroborty, D.; Sarkar, C.; Basu, B.; Dasgupta, P.S.; Basu, S. Catecholamines regulate tumor angiogenesis. Cancer Res. 2009, 69, 3727-3730.
75. Basu, S.; Nagy, J.A.; Pal, S.; Vasile, E.; Eckelhoefer, I.A.; Bliss, V.S.; Manseau, E.J.; Dasgupta, P.S.; Dvorak, H.F.; Mukhopadhyay, D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 2001, 7, 569-574.
76. Sarkar, C.; Chakroborty, D.; Chowdhury, U.R.; Dasgupta, P.S.; Basu, S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 2008, 14, 2502-2510.
77. Bartal, I.; Melamed, R.; Greenfeld, K.; Atzil, S.; Glasner, A.; Domankevich, V.; Naor, R.; Beilin, B.; Yardeni, I.Z.; Ben-Eliyahu, S. Immune perturbations in patients along the perioperative period: Alterations in cell surface markers and leukocyte subtypes before and after surgery. Brain Behav. Immun. 2010, 24, 376-386.
78. Lutgendorf, S.K.; Weinrib, A.Z.; Penedo, F.; Russell, D.; DeGeest, K.; Costanzo, E.S.; Henderson, P.J.; Sephton, S.E.; Rohleder, N.; Lucci, J.A., 3rd; Cole, S.; Sood, A.K.; Lubaroff, D.M. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol. 2008, 26, 4820-4827.
79. Shakhar, G.; Blumenfeld, B. Glucocorticoid involvement in suppression of nk activity following surgery in rats. J. Neuroimmunol. 2003, 138, 83-91.
80. Krukowski, K.; Eddy, J.; Kosik, K.L.; Konley, T.; Janusek, L.W.; Mathews, H.L. Glucocorticoid dysregulation of natural killer cell function through epigenetic modification. Brain Behav. Immun. 2010, doi:10.1016/j.bbi.2010.07.244.
81. Ito, K.; Barnes, P.J.; Adcock, I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone h4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 2000, 20, 6891-6903.
82. Cippitelli, M.; Sica, A.; Viggiano, V.; Ye, J.; Ghosh, P.; Birrer, M.J.; Young, H.A. Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-jun. J. Biol. Chem. 1995, 270, 12548-12556.
83. Elenkov, I.J. Glucocorticoids and the th1/th2 balance. Ann. NY Acad. Sci. 2004, 1024, 138-146.
84. Fahey, A.J.; Robins, R.A.; Kindle, K.B.; Heery, D.M.; Constantinescu, C.S. Effects of glucocorticoids on stat4 activation in human t cells are stimulus-dependent. J. Leukoc. Biol. 2006, 80, 133-144.
85. Franchimont, D.; Galon, J.; Gadina, M.; Visconti, R.; Zhou, Y.; Aringer, M.; Frucht, D.M.; Chrousos, G.P.; O'Shea, J.J. Inhibition of th1 immune response by glucocorticoids: Dexamethasone selectively inhibits il-12-induced stat4 phosphorylation in t lymphocytes. J. Immunol. 2000, 164, 1768-1774.
86. Bodner, G.; Ho, A.; Kreek, M.J. Effect of endogenous cortisol levels on natural killer cell activity in healthy humans. Brain Behav. Immun. 1998, 12, 285-296.
87. Page, G.G.; Ben-Eliyahu, S. Natural killer cell activity and resistance to tumor metastasis in prepubescent rats: Deficient baselines, but invulnerability to stress and beta-adrenergic stimulation. Neuroimmunomodulation 2000, 7, 160-168.
88. Ben-Eliyahu, S.; Rosenne, E.; Sorski, L.; Levi, B. Second thoughts on the role of glucocorticoids in the in vivo suppression of nk activity following stress. In PsychoNeuroImmunology Research Society Annual Meeting; Dublin, Ireland, 2010.
89. Wu, W.; Chaudhuri, S.; Brickley, D.R.; Pang, D.; Karrison, T.; Conzen, S.D. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004, 64, 1757-1764.
90. Wu, W.; Zou, M.; Brickley, D.R.; Pew, T.; Conzen, S.D. Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol. Endocrinol. 2006, 20, 2304-2314.
91. Runnebaum, I.B.; Bruning, A. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor ciap2. Clin. Cancer Res. 2005, 11, 6325-6332.
92. Herr, I.; Gassler, N.; Friess, H.; Buchler, M.W. Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis 2007, 12, 271-291.
93. Yano, A.; Fujii, Y.; Iwai, A.; Kageyama, Y.; Kihara, K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin. Cancer Res. 2006, 12, 3003-3009.
94. Iwai, A.; Fujii, Y.; Kawakami, S.; Takazawa, R.; Kageyama, Y.; Yoshida, M.A.; Kihara, K. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol. Cell. Endocrinol. 2004, 226, 11-17.
95. Sionov, R.V.; Spokoini, R.; Kfir-Erenfeld, S.; Cohen, O.; Yefenof, E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv. Cancer Res. 2008, 101, 127-248.
96. Brand, J.M.; Kirchner, H.; Poppe, C.; Schmucker, P. The effects of general anesthesia on human peripheral immune cell distribution and cytokine production. Clin. Immunol. Immunopathol. 1997, 83, 190-194.
97. Markovic, S.N.; Knight, P.R.; Murasko, D.M. Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiology 1993, 78, 700-706.
98. Schlagenhauff, B.; Ellwanger, U.; Breuninger, H.; Stroebel, W.; Rassner, G.; Garbe, C. Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res. 2000, 10, 165-169.
99. Melamed, R.; Bar-Yosef, S.; Shakhar, G.; Shakhar, K.; Ben-Eliyahu, S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: Mediating mechanisms and prophylactic measures. Anesth. Analg. 2003, 97, 1331-1339.
100. Beilin, B.; Shavit, Y.; Trabekin, E.; Mordashev, B.; Mayburd, E.; Zeidel, A.; Bessler, H. The effects of postoperative pain management on immune response to surgery. Anesth. Analg. 2003, 97, 822-827.
101. Jakob, S.M.; Stanga, Z. Perioperative metabolic changes in patients undergoing cardiac surgery. Nutrition 2010, 26, 349-353.
102. Frank, S.M.; Higgins, M.S.; Breslow, M.J.; Fleisher, L.A.; Gorman, R.B.; Sitzmann, J.V.; Raff, H.; Beattie, C. The catecholamine, cortisol, and hemodynamic responses to mild perioperative hypothermia. A randomized clinical trial. Anesthesiology 1995, 82, 83-93.
103. Gupta, K.; Kshirsagar, S.; Chang, L.; Schwartz, R.; Law, P.Y.; Yee, D.; Hebbel, R.P. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002, 62, 4491-4498.
104. Bar-Yosef, S.; Melamed, R.; Page, G.G.; Shakhar, G.; Shakhar, K.; Ben-Eliyahu, S. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 2001, 94, 1066-1073.
105. Page, G.G.; Blakely, W.P.; Ben-Eliyahu, S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001, 90, 191-199.
106. Tacconi, F.; Pompeo, E.; Sellitri, F.; Mineo, T.C. Surgical stress hormones response is reduced after awake videothoracoscopy. Interact. Cardiovasc. Thorac. Surg. 2010, 10, 666-671.
107. Sessler, D.I.; Ben-Eliyahu, S.; Mascha, E.J.; Parat, M.O.; Buggy, D.J. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contemp. Clin. Trials 2008, 29, 517-526.
108. Exadaktylos, A.K.; Buggy, D.J.; Moriarty, D.C.; Mascha, E.; Sessler, D.I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006, 105, 660-664.
109. Wuethrich, P.Y.; Hsu Schmitz, S.F.; Kessler, T.M.; Thalmann, G.N.; Studer, U.E.; Stueber, F.; Burkhard, F.C. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: A retrospective study. Anesthesiology 2010, 113, 570-576.
110. Manfredi, B.; Sacerdote, P.; Bianchi, M.; Locatelli, L.; Veljic-Radulovic, J.; Panerai, A.E. Evidence for an opioid inhibitory effect on t cell proliferation. J Neuroimmunol 1993, 44, 43-48.
111. Shavit, Y.; Ben-Eliyahu, S.; Zeidel, A.; Beilin, B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 2004, 11, 255-260.
112. Appel, N.M.; Kiritsy-Roy, J.A.; van Loon, G.R. Mu receptors at discrete hypothalamic and brainstem sites mediate opioid peptide-induced increases in central sympathetic outflow. Brain Res 1986, 378, 8-20.
113. Freier, D.O.; Fuchs, B.A. A mechanism of action for morphine-induced immunosuppression: Corticosterone mediates morphine-induced suppression of natural killer cell activity. J. Pharmacol. Exp. Ther. 1994, 270, 1127-1133.
114. Yeager, M.P.; Colacchio, T.A.; Yu, C.T.; Hildebrandt, L.; Howell, A.L.; Weiss, J.; Guyre, P.M. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995, 83, 500-508.
115. Franchi, S.; Panerai, A.E.; Sacerdote, P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav. Immun. 2007, 21, 767-774.
116. Gaspani, L.; Bianchi, M.; Limiroli, E.; Panerai, A.E.; Sacerdote, P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J. Neuroimmunol. 2002, 129, 18-24.
117. Sacerdote, P.; Bianchi, M.; Gaspani, L.; Manfredi, B.; Maucione, A.; Terno, G.; Ammatuna, M.; Panerai, A.E. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth. Analg. 2000, 90, 1411-1414.
118. Malan, T.P., Jr.; Marsh, G.; Hakki, S.I.; Grossman, E.; Traylor, L.; Hubbard, R.C. Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 2003, 98, 950-956.
119. Gach, K.; Szemraj, J.; Wyrebska, A.; Janecka, A. The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol. Biol. Rep. 2010, doi: 10.1007/s11033-010-0222-z.
120. Koodie, L.; Ramakrishnan, S.; Roy, S. Morphine suppresses tumor angiogenesis through a hif-1alpha/p38mapk pathway. Am. J. Pathol. 2010, 177, 984-997.
121. Hernandez-Palazon, J.; Tortosa, J.A.; Martinez-Lage, J.F.; Perez-Flores, D. Intravenous administration of propacetamol reduces morphine consumption after spinal fusion surgery. Anesth. Analg. 2001, 92, 1473-1476.
122. Hodsman, N.B.; Burns, J.; Blyth, A.; Kenny, G.N.; McArdle, C.S.; Rotman, H. The morphine sparing effects of diclofenac sodium following abdominal surgery. Anaesthesia 1987, 42, 1005-1008.
123. Moffat, A.C.; Kenny, G.N.; Prentice, J.W. Postoperative nefopam and diclofenac. Evaluation of their morphine-sparing effect after upper abdominal surgery. Anaesthesia 1990, 45, 302-305.
124. Forget, P.; Vandenhende, J.; Berliere, M.; Machiels, J.P.; Nussbaum, B.; Legrand, C.; De Kock, M. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth. Analg. 2010, 110, 1630-1635.
125. Gupta, A.; Watson, D.I. Effect of laparoscopy on immune function. Br. J. Surg. 2001, 88, 1296-1306.
126. Marana, E.; Scambia, G.; Maussier, M.L.; Parpaglioni, R.; Ferrandina, G.; Meo, F.; Sciarra, M.; Marana, R. Neuroendocrine stress response in patients undergoing benign ovarian cyst surgery by laparoscopy, minilaparotomy, and laparotomy. J. Am. Assoc. Gynecol. Laparosc. 2003, 10, 159-165.
127. Muzii, L.; Marana, R.; Marana, E.; Paielli, F.V.; Meo, F.; Maussier, M.L.; Sciarra, M.; Mancuso, S. Evaluation of stress-related hormones after surgery by laparoscopy or laparotomy. J. Am. Assoc. Gynecol. Laparosc. 1996, 3, 229-234.
128. Friedrich, M.; Rixecker, D.; Friedrich, G. Evaluation of stress-related hormones after surgery. Clin. Exp. Obstet. Gynecol. 1999, 26, 71-75.
129. Wichmann, M.W.; Huttl, T.P.; Winter, H.; Spelsberg, F.; Angele, M.K.; Heiss, M.M.; Jauch, K.W. Immunological effects of laparoscopic vs open colorectal surgery: A prospective clinical study. Arch. Surg. 2005, 140, 692-697.
130. Leung, K.L.; Lai, P.B.; Ho, R.L.; Meng, W.C.; Yiu, R.Y.; Lee, J.F.; Lau, W.Y. Systemic cytokine response after laparoscopic-assisted resection of rectosigmoid carcinoma: A prospective randomized trial. Ann. Surg. 2000, 231, 506-511.
131. Ghezzi, F.; Cromi, A.; Uccella, S.; Siesto, G.; Giudici, S.; Serati, M.; Franchi, M. Laparoscopic versus open surgery for endometrial cancer: A minimum 3-year follow-up study. Ann. Surg. Oncol. 2010, 17, 271-278.
132. Ohtani, H.; Tamamori, Y.; Noguchi, K.; Azuma, T.; Fujimoto, S.; Oba, H.; Aoki, T.; Minami, M.; Hirakawa, K. Meta-analysis of laparoscopy-assisted and open distal gastrectomy for gastric cancer. J. Surg. Res. 2010, doi:10.1016/j.jss.2010.04.008
133. Aldrighetti, L.; Guzzetti, E.; Pulitano, C.; Cipriani, F.; Catena, M.; Paganelli, M.; Ferla, G. Case-matched analysis of totally laparoscopic versus open liver resection for hcc: Short and middle term results. J. Surg. Oncol. 2010, 102, 82-86.
134. Porpiglia, F.; Fiori, C.; Daffara, F.; Zaggia, B.; Bollito, E.; Volante, M.; Berruti, A.; Terzolo, M. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage i and ii adrenocortical cancer. Eur. Urol. 2010, 57, 873-878.
135. McGuire, K.P.; Eisen, S.; Rodriguez, A.; Meade, T.; Cox, C.E.; Khakpour, N. Factors associated with improved outcome after surgery in metastatic breast cancer patients. Am. J. Surg. 2009, 198, 511-515.
136. Smitt, M.C.; Nowels, K.W.; Zdeblick, M.J.; Jeffrey, S.; Carlson, R.W.; Stockdale, F.E.; Goffinet, D.R. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 1995, 76, 259-267.
137. Wazer, D.E.; Jabro, G.; Ruthazer, R.; Schmid, C.; Safaii, H.; Schmidt-Ullrich, R.K. Extent of margin positivity as a predictor for local recurrence after breast conserving irradiation. Radiat. Oncol. Investig. 1999, 7, 111-117.
138. Liu, J.; Hao, X.S.; Yu, Y.; Fang, Z.Y.; Liu, J.T.; Niu, Y.; Fentiman, I.S. Long-term results of breast conservation in chinese women with breast cancer. Breast J. 2009, 15, 296-298.
139. Nesvold, I.L.; Dahl, A.A.; Lokkevik, E.; Marit Mengshoel, A.; Fossa, S.D. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol. 2008, 47, 835-842.
140. El-Tamer, M.B.; Ward, B.M.; Schifftner, T.; Neumayer, L.; Khuri, S.; Henderson, W. Morbidity and mortality following breast cancer surgery in women: National benchmarks for standards of care. Ann. Surg. 2007, 245, 665-671.
141. Poggi, M.M.; Danforth, D.N.; Sciuto, L.C.; Smith, S.L.; Steinberg, S.M.; Liewehr, D.J.; Menard, C.; Lippman, M.E.; Lichter, A.S.; Altemus, R.M. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The national cancer institute randomized trial. Cancer 2003, 98, 697-702.
142. Veronesi, U.; Cascinelli, N.; Mariani, L.; Greco, M.; Saccozzi, R.; Luini, A.; Aguilar, M.; Marubini, E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 2002, 347, 1227-1232.
143. Hrushesky, W.J.; Bluming, A.Z.; Gruber, S.A.; Sothern, R.B. Menstrual influence on surgical cure of breast cancer. Lancet 1989, 2, 949-952.
144. Grant, C.S.; Ingle, J.N.; Suman, V.J.; Dumesic, D.A.; Wickerham, D.L.; Gelber, R.D.; Flynn, P.J.; Weir, L.M.; Intra, M.; Jones, W.O.; Perez, E.A.; Hartmann, L.C. Menstrual cycle and surgical treatment of breast cancer: Findings from the ncctg n9431 study. J. Clin. Oncol. 2009, 27, 3620-3626.
145. Thorpe, H.; Brown, S.R.; Sainsbury, J.R.; Perren, T.J.; Hiley, V.; Dowsett, M.; Nejim, A.; Brown, J.M. Timing of breast cancer surgery in relation to menstrual cycle phase: No effect on 3-year prognosis: The its study. Br. J. Cancer 2008, 98, 39-44.
146. Kroman, N. Timing of breast cancer surgery in relation to the menstrual cycle--the rise and fall of a hypothesis. Acta Oncol. 2008, 47, 576-579.
147. Ben-Eliyahu, S.; Page, G.G.; Shakhar, G.; Taylor, A.N. Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: Possible role of oestradiol and natural killer cells. Br. J. Cancer 1996, 74, 1900-1907.
148. Ben-Eliyahu, S.; Shakhar, G.; Shakhar, K.; Melamed, R. Timing within the oestrous cycle modulates adrenergic suppression of nk activity and resistance to metastasis: Possible clinical implications. Br. J. Cancer 2000, 83, 1747-1754.
149. Page, G.G.; Ben-Eliyahu, S. Increased surgery-induced metastasis and suppressed natural killer cell activity during proestrus/estrus in rats. Breast Cancer Res. Treat. 1997, 45, 159-167.
150. Shakhar, K.; Shakhar, G.; Rosenne, E.; Ben-Eliyahu, S. Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of nk cell activity. Br. J. Cancer 2000, 83, 1630-1636.
151. Wheeldon, N.M.; Newnham, D.M.; Coutie, W.J.; Peters, J.A.; McDevitt, D.G.; Lipworth, B.J. Influence of sex-steroid hormones on the regulation of lymphocyte beta 2-adrenoceptors during the menstrual cycle. Br. J. Clin. Pharmacol. 1994, 37, 583-588.
152. Pierdominici, M.; Maselli, A.; Colasanti, T.; Giammarioli, A.M.; Delunardo, F.; Vacirca, D.; Sanchez, M.; Giovannetti, A.; Malorni, W.; Ortona, E. Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol. Lett. 2010, 132, 79-85.
153. Curran, E.M.; Berghaus, L.J.; Vernetti, N.J.; Saporita, A.J.; Lubahn, D.B.; Estes, D.M. Natural killer cells express estrogen receptor-alpha and estrogen receptor-beta and can respond to estrogen via a non-estrogen receptor-alpha-mediated pathway. Cell. Immunol. 2001, 214, 12-20.
154. Hao, S.; Zhao, J.; Zhou, J.; Zhao, S.; Hu, Y.; Hou, Y. Modulation of 17beta-estradiol on the number and cytotoxicity of nk cells in vivo related to mcm and activating receptors. Int. Immunopharmacol. 2007, 7, 1765-1775.
155. Hao, S.; Li, P.; Zhao, J.; Hu, Y.; Hou, Y. 17beta-estradiol suppresses cytotoxicity and proliferative capacity of murine splenic nk1.1+ cells. Cell. Mol. Immunol. 2008, 5, 357-364.
156. Wood, P.A.; Bove, K.; You, S.; Chambers, A.; Hrushesky, W.J. Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol. Cancer Ther. 2005, 4, 1065-1075.
157. White, C.M.; Talati, R.; Phung, O.J.; Baker, W.L.; Reinhart, K.; Sedrakyan, A.; Kluger, J.; Coleman, C.I. Benefits and risks associated with beta-blocker prophylaxis in noncardiac surgery. Am. J. Health Syst. Pharm. 2010, 67, 523-530.
158. Avraham, R.; Benish, M.; Inbar, S.; Bartal, I.; Rosenne, E.; Ben-Eliyahu, S. Synergism between immunostimulation and prevention of surgery-induced immune suppression: An approach to reduce post-operative tumor progression. Brain Behav. Immun. 2010, 24, 952-958.
159. Weiss, J.M.; Subleski, J.J.; Wigginton, J.M.; Wiltrout, R.H. Immunotherapy of cancer by il-12-based cytokine combinations. Expert Opin. Biol. Ther.2007, 7, 1705-1721.
160. Wigginton, J.M.; Wiltrout, R.H. Il-12/il-2 combination cytokine therapy for solid tumours: Translation from bench to bedside. Expert Opin. Biol. Ther. 2002, 2, 513-524.
161. Murad, Y.M.; Clay, T.M. Cpg oligodeoxynucleotides as tlr9 agonists: Therapeutic applications in cancer. Bio. Drugs 2009, 23, 361-375.
162. Seya, T.; Matsumoto, M. The extrinsic rna-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunol. Immunother. 2009, 58, 1175-1184.
163. Schwartz, Y.; Avraham, R.; Benish, M.; Rosenne, E.; Ben-Eliyahu, S. Prophylactic il-12 treatment reduces postoperative metastasis: Mediation by increased numbers but not cytotoxicity of nk cells. Breast Cancer Res. Treat. 2008, 107, 211-223.
164. Goldfarb, Y.; Benish, M.; Rosenne, E.; Melamed, R.; Levi, B.; Glasner, A.; Ben-Eliyahu, S. Cpg-c oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on nk cytotoxicity and metastatic dissemination. J. Immunother. 2009, 32, 280-291.
165. Goldfarb, Y.; Levi, B.; Sorski, L.; Frenkel, D.; Ben-Eliyahu, S. Cpg-c immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: Potential implications for clinical use. Brain Behav. Immun. 2010, doi:10.1016/j.bbi.2010.07.242.
166. R, A.; S, B.-E. Neuroendocrine regulation of cancer progression: Ii. Immunological mechanisms, clinical relevance, and prophylactic measures. Fourth ed.; Elsevier: Amsterdam, 2007; pp. 251-265.
167. Benjamin, B.; Hazut, O.; Shaashua, L.; Benish, M.; Zmora, N.; Barshack, I.; Hoffman, A.; Ben-Eliyahu, S.; Zmora, O. Effect of beta blocker combined with cox-2 inhibitor on colonic anastomosis in rats. Int. J. Colorectal. Dis. 2010, 25, 1459-1461.